In the last year, multiple insiders have substantially increased their holdings of Integra LifeSciences Holdings Corporation (NASDAQ:IART) stock, indicating that insiders' optimism about the company's prospects has increased.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for Integra LifeSciences Holdings

The Last 12 Months Of Insider Transactions At Integra LifeSciences Holdings

In the last twelve months, the biggest single purchase by an insider was when Executive Chairman Stuart Essig bought US$1.5m worth of shares at a price of US$28.49 per share. Even though the purchase was made at a significantly lower price than the recent price (US$31.74), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

Happily, we note that in the last year insiders paid US$2.5m for 88.99k shares. But insiders sold 1.18k shares worth US$52k. In the last twelve months there was more buying than selling by Integra LifeSciences Holdings insiders. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction! insider-trading-volume

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this freelist of companies. (Hint: insiders have been buying them).

Insiders At Integra LifeSciences Holdings Have Bought Stock Recently

It's good to see that Integra LifeSciences Holdings insiders have made notable investments in the company's shares. Not only was there no selling that we can see, but they collectively bought US$2.5m worth of shares. This could be interpreted as suggesting a positive outlook.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that Integra LifeSciences Holdings insiders own 3.3% of the company, worth about US$78m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.



So What Does This Data Suggest About Integra LifeSciences Holdings Insiders?

It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. Given that insiders also own a fair bit of Integra LifeSciences Holdings we think they are probably pretty confident of a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Every company has risks, and we've spotted 3 warning signs for Integra LifeSciences Holdings (of which 1 can't be ignored!) you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this freelist of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]